Human Immunodeficiency Virus (HIV) Infections (AIDS) is an indication for drug development with over 520 pipeline drugs currently active. According to GlobalData, preregistered drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 95.74% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Human Immunodeficiency Virus (HIV) Infections (AIDS) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Human Immunodeficiency Virus (HIV) Infections (AIDS) overview
Human Immunodeficiency Virus (HIV) infections, leading to Acquired Immunodeficiency Syndrome (AIDS), continue to be a global health concern, particularly in vulnerable populations. HIV weakens the immune system, making individuals more susceptible to infections and other diseases. While advancements in antiretroviral therapy have transformed HIV from a fatal diagnosis to a manageable chronic condition, access to treatment remains unequal across regions. Stigma and discrimination further hinder prevention efforts and access to care. Comprehensive prevention strategies including education, testing, and access to treatment are crucial in curbing transmission rates and improving the quality of life for those living with HIV/AIDS. Ongoing research and community support are essential in achieving the goal of ending the HIV/AIDS pandemic.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Human Immunodeficiency Virus (HIV) Infections (AIDS), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
